# Hyperion Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hyperion-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.hyperiontx.com
- Total disclosed funding: $105M
- Latest round: Series D (Oct 26, 2011)
- Investors on record: 6

## About

Hyperion Therapeutics is a biotechnology company focused on developing innovative therapies for patients suffering from rare diseases and metabolic disorders. The company aims to enhance patient outcomes through its specialized treatments.Hyperion Therapeutics, founded in 2006, is headquartered in San Francisco, US. The company specializes in the development of treatments for rare diseases and metabolic disorders. In July 2012, Hyperion Therapeutics raised USD 50 mn in an IPO, selling 5 million shares at USD 10 each, and subsequently listed on NASDAQ under the ticker symbol HPTX. The company has completed a total of 8 deals, with the most recent deal occurring on July 26, 2012. Horizon Therapeutics plc was the lead investor in its latest funding round, classified as an Add-on and Trade Sale.Hyperion Therapeutics develops specialized therapies aimed at addressing unmet medical needs in rare diseases and metabolic disorders. Their product offerings focus on improving patient health through targeted biologic treatments designed for conditions with limited existing treatment options.In 2014, Hyperion Therapeutics reported a revenue of USD 113.58 mn, with an EBITDA of USD 1.94 mn for the same year.Hyperion Therapeutics plans to use the proceeds from its recent IPO to accelerate research and development of new therapeutic products specifically targeting rare diseases. The company is also exploring opportunities to expand its market presence into Europe and Asia-Pacific regions by 2024, aiming to reach more patients in need of its innovative treatments.

## Funding rounds

- Series D, Oct 26, 2011, $7.5M — Highland Capital Partners, New Enterprise Associates, Sofinnova Investments, Panorama Capital, Bay City Capital
- Series D, Apr 1, 2011, $17M — Highland Capital Partners, New Enterprise Associates, Sofinnova Investments, Panorama Capital, Bay City Capital
- Series D, Jun 30, 2009, $60M — Highland Capital Partners, New Enterprise Associates, Sofinnova Investments, Panorama Capital, Bay City Capital
- Series B, Sep 5, 2007, $20M — Highland Capital Partners, New Enterprise Associates, Sofinnova Investments, WRF Capital

## Investors

- Highland Capital Partners (https://capitalatlas.ai/funds/highland-capital-partners) — Series B, Series D
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series B, Series D
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series B, Series D
- WRF Capital (https://capitalatlas.ai/funds/wrf-capital) — Series B
- Panorama Capital — Series D
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series D